muscarinic M2/M4 agonists (Lilly)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namemuscarinic M2/M4 agonists (Lilly)
Drug Alias Namemuscarinic M2/M4 agonists (Lilly/Novo Nordisk)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M2 agonistsDopamine receptors antagonistsMuscarinic acetylcholine receptor M4 agonists
TargetsDopamine receptorsMuscarinic acetylcholine receptor M2Muscarinic acetylcholine receptor M4
Therapy Area/IndicationsPsychotic DisordersAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmark
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And CompanyNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsPsychotic DisordersAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A